FISH检测乳腺癌组织HER-2原癌基因50例分析

目的:探讨荧光免疫原位杂交法(FISH)检查乳腺癌HER-2基因扩增在临床中的应用价值。方法:选取50例乳腺癌手术患者,免疫组化染色方法检查乳腺癌组织中HER-2蛋白表达,FISH检查HER-2基因扩增情况,比较二者之间差异。结果:50例乳腺癌中免疫组化方法检测HER-2蛋白表达,者7例,者21例,+者17例;FISH检查50例中有8例出现HER-2基因扩增,42例无扩增。两种检测方法检测阳性结果有显著性差异(P<0.01)。结论:免疫组化检测可做为HER-2表达状态的初筛,对于初筛阳性患者有必要进行FISH检测,有助于指导临床应用赫赛汀(Herceptin)的治疗及对患者预后的判断。

Detection of HER-2/neu Oncogene by fluorescence in situ hybridization in 50 patients of breast cancer

Objective:To detect the HER-2 gene amplification by fluorescence in situ hybridization(FISH) in breast cancer and evaluate their clinical significance.Methods:50 patients which in-patient from August 2007 to July 2008 were detected the expression of HER-2 protein by immunohistochemical staining and the HER-2 gene amplification by FISH after surgery.Compared the difference between the two methods.Results:Of 50 patients,7 cases(14%) expression of HER-2 protein were strongly positive(),21 cases(42%) were positive(),and 17 cases(34%) were weak positive(+),and the HER-2 gene amplification were 8 cases(16%),42 cases were no amplification.There were significant difference about positive between two methods(P<0.01).Conclusion:The immunohistochemistry can be used in initial screening of HER-2 protein expression.It is necessary to detect the HER-2 gene amplification by FISH in positive patients,which help to guide the treatment of Herceptin and prognosis of patients.